Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Dennis J. Slamon, Nicholas C. Turner et al.|The Lancet Oncology|2016Cited by 1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Dennis J. Slamon et al.|New England Journal of Medicine|2018Cited by 1.3k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in CancerBarzin Y. Nabet, Andy J. Minn, Yu Qiu et al.|Cell|2017Cited by 448
(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353